NFL Biosciences S.A. (82F)

Overview

NFL Biosciences SA is a pioneering biotechnology entity dedicated to the development of innovative natural solutions aimed at aiding individuals in overcoming addiction, particularly smoking. With its establishment in 2006, the company positioned itself in the biotech industry with a focus on leveraging natural substances to combat nicotine dependence. Based in Castelnau-le-Lez, France, NFL Biosciences SA is at the forefront of research and development in the realm of addiction withdrawal therapies, demonstrating a commitment to addressing public health challenges related to tobacco use.

Products and Services

NFL-101 is a tobacco extract undergoing Phase III clinical trials, designed to help smokers quit by targeting the mechanisms of smoking addiction. This flagship product encapsulates the company’s innovative approach to utilizing natural sources for medical interventions, representing a significant advancement in addiction therapy.

NFL-201, a blend of cannabis and tobacco extracts, is in the preclinical stage of development. This novel formulation aims to explore the synergistic effects of these plants to offer a potentially effective remedy for nicotine dependence, illustrating the company's commitment to diversifying its portfolio of addiction treatment options.

NFL-301 is a botanical extract derived from traditional Chinese medicine, also in the preclinical stage. The usage of ancient medical knowledge signifies NFL Biosciences SA’s endeavor to integrate historical wisdom with modern science to create innovative solutions for today’s health issues, specifically smoking addiction.